CytomX Therapeutics Inc. said Hoyoung Huh would step down as chairman, effective Dec. 31.

The company appointed President and CEO Sean McCarthy to replace Hoyoung as chairman and James Meyers as a board member.

Meyers serves as a director at Arbutus Biopharma Corp., a public biopharmaceutical company. In addition, he was executive vice president of worldwide commercial operations at Gilead Sciences Inc.

South San Francisco, Calif.-based CytomX Therapeutics operates as an oncology-focused biopharmaceutical company.